4//SEC Filing
MCGRATH JOHN 4
Accession 0001209191-18-011664
CIK 0001604464other
Filed
Feb 19, 7:00 PM ET
Accepted
Feb 20, 8:22 PM ET
Size
16.1 KB
Accession
0001209191-18-011664
Insider Transaction Report
Form 4
MCGRATH JOHN
Chief Financial Officer
Transactions
- Sale
Common Stock
2018-02-16$48.08/sh−2,500$120,200→ 94,762 total - Exercise/Conversion
Common Stock
2018-02-15+5,132→ 104,188 total - Tax Payment
Common Stock
2018-02-15$47.05/sh−2,926$137,668→ 101,262 total - Sale
Common Stock
2018-02-16$46.93/sh−4,000$187,720→ 97,262 total - Sale
Common Stock
2018-02-15$46.77/sh−6,500$304,005→ 99,056 total - Exercise/Conversion
Restricted Stock Units
2018-02-15−5,132→ 0 total(indirect: See footnote)→ Common Stock (5,132 underlying)
Footnotes (11)
- [F1]Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016.
- [F10]The earlier of (i) December 12, 2020 or (ii) the recipient's termination date.
- [F11]The shares are held by the David B. Horowitz and John McGrath Jr. Revocable Living Trust dated 6/3/11, of which the Reporting Person is trustee.
- [F2]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $46.50 to $47.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]Shares issued upon settlement of vested restricted stock units ("RSUs").
- [F4]Shares withheld to cover tax obligation from settlement of vested restricted stock units.
- [F5]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $46.65 to $47.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F6]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $47.70 to $48.325. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F7]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement.
- [F8]The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on January 6, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date.
- [F9]Fully vested.
Documents
Issuer
Atara Biotherapeutics, Inc.
CIK 0001604464
Entity typeother
Related Parties
1- filerCIK 0001205442
Filing Metadata
- Form type
- 4
- Filed
- Feb 19, 7:00 PM ET
- Accepted
- Feb 20, 8:22 PM ET
- Size
- 16.1 KB